Study on 24-hour Na excretion effect of sustained ARB Azilsartan and its effect on blood pressure

Study on 24-hour Na excretion effect of sustained ARB Azilsartan and its effect on blood pressure - Study on the effect of Na excretion and blood pressure of Azilsartan

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000032240

Enrollment

Registered

2018-04-16

Start date

2018-03-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertensive patients with complication of chronic kidney disease

Interventions

Intervention group with Azilsartan for 12days

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients over 20 years of age (2) CKD patients with hypertension thought to be unnecessary for dialysis introduction during the study period (3) Patients for whom consent is documented for participation in this study (4) Patients who have consent to hospitalization for participation in this study

Exclusion criteria

Exclusion criteria: (1) Patients who are receiving ARB, ACE inhibitors, renin inhibitors within 2 weeks (2) Patients falling under the contraindications of Azir Sultan (3) Patients with severe hypertension (4) Patients with CKDstage 5 or higher (5) patients with insulin treatment (6) Patients who are pregnant or nursing (7) Patients with severe liver dysfunction (8) Patients who are judged inappropriate for the research subject by the attending physician

Design outcomes

Primary

Measure	Time frame
Urinary Na excretion rate	—

Countries

Japan

Contacts

Public ContactYuki Kawai

Yokohama City University Graduate School of Medicine Department of Medical Science and Cardiorenal Medicine

ykawai2017@gmail.com045-787-2800

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026